PFEPfizerSigning up patients
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Carcinoma · Non-Small Cell Lung Cancer Metastatic · Non-Small Cell Lung Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 680 (planned)
- Started
- Sep 29, 2025
- Main results expected
- Mar 10, 2028
- Fully finished
- Mar 10, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival
Measured over: Approximately 5 years
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-09 15:36 UTC · paperwork · other
old: null
new: null
details: {"sections":["referencesModule"]}
Trial ID NCT07144280 · record last updated 2026-11-05 · checked 2026-11-09 15:42 UTC